National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Upadacitinib (Rinvoq®) is indicated for the treatment of moderate-to-severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. Upadacitinib may be used as monotherapy or in combination with methotrexate.

 

NCPE Assessment Process Complete
Rapid review commissioned 29/10/2019
Rapid review completed 10/12/2019
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of upadacitinib (Rinvoq®) compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.